J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2247KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 99(5): 279-284, 1998

Feature topic

POSTSURGICAL ADJUVANT IMMUNOTHERAPY AGAINST PRIMARY NON-SMALL CELL LUNG CANCER.

1) Division of Thoracic Diseases, Chiba Cancer Center, Chiba, Japan
2) Department of Pulmonary Cancer Research, Chiba university School of Medicine, Chiba, Japan

Hideki  Kimura1), Naomichi  Iwai1), Makoto Suzuki2), Yoshiyuki Takahashi2)

The prognosis of lung cancer patients is generally poor even when they have undergone complete resection of primary tumors and systemic lymph node dissection. This is mainly attributed to micrometastases which have already developed by the time of surgery and the fact that local therapies cannot eliminate all cancer cells from the body. We developed a multimodality combination therapy for primary non-small cell lung cancer consisting of surgery, chemotherapy, and adoptive immunotherapy using interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cells. The results of a randomized study indicated that the survival rate of the IL-2, LAK adoptive immunotherapy group was significantly higher than that of the control group. In conclusion, IL-2, LAK adoptive immunotherapy is an effective and promising modality which will compensate for the deficiencies of other therapies.

To next page >>

To read the PDF file you will need Adobe Reader installed on your computer.